Cisen Pharmaceutical Co., Ltd. (SHA:603367)
12.77
-0.21 (-1.62%)
Nov 13, 2026, 3:00 PM CST
Cisen Pharmaceutical Revenue
Cisen Pharmaceutical had revenue of 782.16M CNY in the quarter ending September 30, 2026, a decrease of -7.33%. This brings the company's total for the last twelve months to 3.34B, down -6.37% year-over-year. In the year 2025, Cisen Pharmaceutical had annual revenue of 3.44B, down -13.48%. That makes Cisen Pharmaceutical the 11,276th largest company in the world by revenue and 1,890th in China.
Revenue (ttm)
3.34B
Revenue Growth
-6.37%
P/S Ratio
1.73
Revenue / Employee
1.07M
Employees
3,114
Market Cap
5.78B
Revenue by Geography
- China 3.36B 98.1%
- Overseas 64.88M 1.9%
Fiscal year ended Dec 31, 2025 See the full Cisen Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.44B | -536.86M | -13.48% |
| Dec 31, 2024 | 3.98B | -480.78M | -10.77% |
| Dec 31, 2023 | 4.46B | 396.26M | 9.75% |
| Dec 31, 2022 | 4.07B | 283.50M | 7.49% |
| Dec 31, 2021 | 3.78B | 108.43M | 2.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HPGC Renmintongtai Pharmaceutical | 10.64B |
| Guizhou Xinbang Pharmaceutical | 5.02B |
| Guizhou Bailing Group Pharmaceutical | 2.36B |
| Jinghua Pharmaceutical Group | 1.48B |
| Bide Pharmatech | 1.40B |
| Hunan Er-Kang Pharmaceutical | 1.11B |
| Beijing Sun-Novo Pharmaceutical Research | 1.01B |
| Wanbangde Pharmaceutical Holding Group | 853.52M |